Citi opens ‘positive catalyst watch’ on Tandem Diabetes into earnings

Citi opened a “30-day positive catalyst watch” on shares of Tandem Diabetes while keeping a Buy rating on the name with a $57 price target. Given the recent pullback in the stock and Citi’s expectations for a beat and raise with the Q2 print, Tandem should see renewal momentum and recovering new patient starts against a guide that screens conservatively, the analyst tells investors in a research note.